United States Federal Circuit

In an invalidity dispute for a patent relating to Alzheimer's disease treatment, summary judgment to defendant is reversed and remanded for determination whether reference to "Nucleic Acids for Diagnosing and Modeling Alzheimer's Disease" was an enabling disclosure.

Appellate Information

• Decided 10/02/2003
• Published 10/02/2003

Judges

• PAULINE NEWMAN, Circuit Judge., Before NEWMAN, GAJARSA, and DYK, Circuit Judges.

Court

• United States Federal Circuit

Counsel

• For Appellant:
  
• Lynn H. Pasahow,Fenwick & West LLP, of Mountain View, CA, for plaintiffs-appellants.   Of counsel were Beth H. Parker, Mary T. Huser, and S. Christian Platt, Bingham McCutchen LLP, of Palo Alto, CA;  Thomas S. Hixson, Bingham McCutchen, LLP, of San Francisco, CA;  and Charlene M. Morrow, Fenwick & West LLP, of Mountain View, CA.


• For Appellees:
  
• Robert E. Hillman, Fish & Richardson, P.C., of Boston, MA, for defendant-appellee.   Of counsel were Shelley K. Wessels, Karen I. Boyd, and Kurtis D. MacFerrin, Fish & Richardson, P.C., of Menlo Park, CA. Also of counsel was Chad A. Hanson, Fish & Richardson, P.C., of Minneapolis, MN.